MAZE

Maze Therapeutics, Inc./$MAZE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Maze Therapeutics, Inc.

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Ticker

$MAZE
Primary listing

Industry

Pharmaceuticals

Employees

125

ISIN

US5787841007

MAZE Metrics

BasicAdvanced
$685M
46.62
$0.34
-
-

Bulls say / Bears say

Maze Therapeutics successfully completed an upsized IPO in February 2025, raising approximately $140 million, providing substantial capital to advance its clinical programs. (Maze Therapeutics Press Release)
The company reported positive Phase 1 results for MZE829 in October 2024, demonstrating good tolerability and supporting once-daily dosing, which could enhance patient compliance. (GlobeNewswire)
Analysts from JPMorgan Chase & Co. initiated coverage on Maze Therapeutics with an 'overweight' rating and a $30.00 price target, indicating strong confidence in the company's growth potential. (American Banking and Market News)
Despite the successful IPO, Maze Therapeutics reported a net loss in Q4 2024, reflecting ongoing financial challenges common in clinical-stage biopharmaceutical companies. (GlobeNewswire)
The company's lead programs, MZE829 and MZE782, are still in early clinical stages, and any delays or failures in these trials could negatively impact investor confidence. (GlobeNewswire)
Maze Therapeutics operates in a highly competitive biopharmaceutical sector, facing potential challenges from larger, more established companies with greater resources. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MAZE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs